Philip S. Low joined Quince Therapeutics’ Board of Directors in May 2022. Dr. Low is the Presidential Scholar in Drug Discovery and the Ralph C. Corley Distinguished Professor of Chemistry at Purdue University. He has spent more than 30 years exploring novel methods for targeted drug discovery, including target identification, drug design and synthesis, animal testing, and human clinical evaluation. Dr. Low has published more than 500 scientific articles and has more than 360 U.S. patents and patents pending. Eight drugs stemming from his research are currently undergoing human clinical trials and seven companies (Endocyte Inc., OnTarget Laboratories Inc., Novosteo Inc., Erythrocure Inc., Umoja Biopharma Inc., Morphimmune Inc. and Eradivir Inc.) have been founded to commercialize these discoveries. He has received an NIH MERIT Award, the ACS Award for Cancer Research (Sosnovsky Award), the AACR Award for Outstanding Chemistry in Cancer Research, both of Purdue’s awards for outstanding research (McCoy and Sigma Xi Awards), the University’s highest career achievement award (Morrill Award), the American Chemical Society’s Esselen Award and numerous other National and International awards. Dr. Low received his B.S. in Chemistry from Brigham Young University and his Ph.D. in Biochemistry from the University of California, San Diego.